Abstract
The conventional NOD/SCID xenotransplant model provides a powerful tool to characterize human hematopoietic stem cells. This system relies on IV injection of transplanted cells, with subsequent circulation through the blood prior to homing to appropriate niches. Two major limitations of this model are the presence of residual host factors that resist engraftment (i.e. NK cells and macrophages) and inability to detect stem cells that are incapable of homing or surviving in the circulation. We previously showed that rapid-SRC (R-SRC) were more efficiently detected by direct intrafemoral (IF) injection compared to IV transplantation (Nat Med 2003). Additionally, others showed that depletion of NK cell activity detects a short-term repopulating cell indicating that immune recognition is also important. R-SRC are found in the Lin-CD34+CD38+/lo population and produce a robust human erythromyeloid graft 2 weeks post-transplant. R-SRC are critical for stem cell therapies that require rapid engraftment and their characterization requires an efficient assay. To determine the role of cellular resistance factors we compared human engraftment in NOD/SCID mice, NOD/SCID-B2 microglobulin-null (NOD/SCID-B2m−/−) mice that are depleted of NK cells, or we administered a neutralizing antibody against the IL-2R B-chain (CD122) to NOD/SCID mice. CD122 depletes several populations including NK cells and macrophages. 4–5 x 104 Lin-CD34+CD38lo cells purified from CB were injected IF or IV into these recipients and human engraftment was determined at 2 weeks post-transplant to assay for R-SRC. In addition to determining engraftment levels, we also used the IF assay to gain insight into migration/mobilization function of R-SRC by examining human engraftment in other bones. Human myelolymphoid (CD45+) engraftment in the injected femur (RF) was significantly higher (p<0.05) in IF injected anti-CD122 treated NOD/SCID mice compared to all other groups. Since IF NOD/SCID-B2M−/ − mice had the next highest engraftment levels, these data indicate that R-SRC are very sensitive to NK activity. However the data clearly show that CD122+ cells also play a significant role in resisting stem cell engraftment. Importantly, CD122+ cells markedly affected R-SRC migration/mobilization since there was significantly higher engraftment in non-injected bones from anti-CD122 treated mice even when compared to the NOD/SCID-B2M−/ − mice. Our previous clonal analysis showed that R-SRC that are found in non-injected bones also self-renew in the injected bone before migration. We conclude that in addition to NK cells, CD122+ cells (likely macrophages) prevent the direct engraftment of R-SRC when delivered by IF or IV injection as well as their subsequent in vivo self-renewal and/or migration. Modification to the standard NOD/SCID assay by IF injection in combination with anti-CD122 provides a powerful tool to identify novel populations of stem cells as well as insight into fundamentally important properties of stem cell biology and transplantation.
Mouse (n) . | Injection . | Tissue . | CD45+ (%) . | Erythroid (CD45-CD36+glyA+ (%) . | Total * . |
---|---|---|---|---|---|
RF-injected rt femur;BM-noninjected lt femur, pelvis, two tibiae;glyA-glycophorinA;*-total CD45+plus CD45-erythroid engraftment | |||||
NOD/SCID anti-CD122 (15) | IF | RF | 13.2 | 41.4 | 54.6 |
BM | 4.9 | 23.3 | 28.1 | ||
NOD/SCID anti-CD122 (18) | IV | RF | 5.3 | 26.5 | 31.8 |
BM | 6.6 | 33.5 | 40.1 | ||
NOD/SCID (13) | IF | RF | 3.6 | 11.9 | 15.5 |
BM | 0.9 | 2.6 | 3.5 | ||
NOD/SCID (15) | IV | RF | 1.4 | 3.9 | 5.3 |
BM | 1.3 | 4.2 | 5.5 | ||
NOD/SCID/B2M−/ − (6) | IF | RF | 7.2 | 31.9 | 39.1 |
BM | 1.8 | 7.0 | 8.8 | ||
NOD/SCID/B2M−/ − (9) | IV | RF | 3.5 | 4.9 | 8.3 |
BM | 3.4 | 9.4 | 12.8 |
Mouse (n) . | Injection . | Tissue . | CD45+ (%) . | Erythroid (CD45-CD36+glyA+ (%) . | Total * . |
---|---|---|---|---|---|
RF-injected rt femur;BM-noninjected lt femur, pelvis, two tibiae;glyA-glycophorinA;*-total CD45+plus CD45-erythroid engraftment | |||||
NOD/SCID anti-CD122 (15) | IF | RF | 13.2 | 41.4 | 54.6 |
BM | 4.9 | 23.3 | 28.1 | ||
NOD/SCID anti-CD122 (18) | IV | RF | 5.3 | 26.5 | 31.8 |
BM | 6.6 | 33.5 | 40.1 | ||
NOD/SCID (13) | IF | RF | 3.6 | 11.9 | 15.5 |
BM | 0.9 | 2.6 | 3.5 | ||
NOD/SCID (15) | IV | RF | 1.4 | 3.9 | 5.3 |
BM | 1.3 | 4.2 | 5.5 | ||
NOD/SCID/B2M−/ − (6) | IF | RF | 7.2 | 31.9 | 39.1 |
BM | 1.8 | 7.0 | 8.8 | ||
NOD/SCID/B2M−/ − (9) | IV | RF | 3.5 | 4.9 | 8.3 |
BM | 3.4 | 9.4 | 12.8 |
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal